.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Covington
Moodys
Baxter
Colorcon
Novartis
Express Scripts
Cerilliant
Argus Health
Mallinckrodt

Generated: November 20, 2017

DrugPatentWatch Database Preview

Teva Womens Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA WOMENS, and when can generic versions of TEVA WOMENS drugs launch?

TEVA WOMENS has nine approved drugs.

There are three US patents protecting TEVA WOMENS drugs.

There are twenty-four patent family members on TEVA WOMENS drugs in sixteen countries and nine supplementary protection certificates in seven countries.

Summary for Teva Womens

International Patents:24
US Patents:3
Tradenames:15
Ingredients:9
NDAs:9
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Womens
ADDERALL 15
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
TABLET;ORAL011522-013Aug 31, 2000DISCNYesNo► Subscribe► SubscribeY► Subscribe
Teva Womens
ZEBETA
bisoprolol fumarate
TABLET;ORAL019982-001Jul 31, 1992DISCNNoNo► Subscribe► Subscribe► Subscribe
Teva Womens
ADDERALL 10
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
TABLET;ORAL011522-007Feb 13, 1996DISCNYesNo► Subscribe► SubscribeY► Subscribe
Teva Womens
ANTABUSE
disulfiram
TABLET;ORAL007883-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Teva Womens
ANTABUSE
disulfiram
TABLET;ORAL007883-003Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Teva Womens
ADDERALL 5
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
TABLET;ORAL011522-009May 12, 1997DISCNYesNo► Subscribe► SubscribeY► Subscribe
Teva Womens
SYNTHETIC CONJUGATED ESTROGENS A
estrogens, conjugated synthetic a
CREAM;VAGINAL021788-001Nov 28, 2008DISCNNoNo► Subscribe► Subscribe► Subscribe
Teva Womens
PARAGARD T 380A
copper
INTRAUTERINE DEVICE;INTRAUTERINE018680-001Nov 15, 1984RXYesYes► Subscribe► Subscribe► Subscribe
Teva Womens
DIAMOX
acetazolamide sodium
INJECTABLE;INJECTION009388-001Dec 5, 1990DISCNYesNo► Subscribe► Subscribe► Subscribe
Teva Womens
ADDERALL 20
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
TABLET;ORAL011522-008Feb 13, 1996DISCNYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Teva Womens

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Womens
PREFEST
estradiol; norgestimate
TABLET;ORAL021040-001Oct 22, 1999► Subscribe► Subscribe
Teva Womens
ZEBETA
bisoprolol fumarate
TABLET;ORAL019982-002Jul 31, 1992► Subscribe► Subscribe
Teva Womens
ZEBETA
bisoprolol fumarate
TABLET;ORAL019982-001Jul 31, 1992► Subscribe► Subscribe
Teva Womens
PREFEST
estradiol; norgestimate
TABLET;ORAL021040-001Oct 22, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TEVA WOMENS drugs

Drugname Dosage Strength Tradename Submissiondate
dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfa
Tablets5 mg, 10 mg, 20 mg, 30 mg
ADDERALL 30
11/18/2009

Non-Orange Book Patents for Teva Womens

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,078,394Low dose estrogen interrupted hormone replacement therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Teva Womens Drugs

Country Document Number Estimated Expiration
Poland350854► Subscribe
Turkey200102860► Subscribe
Japan2003504406► Subscribe
Poland202043► Subscribe
Czech Republic20013493► Subscribe
European Patent Office1202739► Subscribe
MexicoPA01009813► Subscribe
Hungary0200416► Subscribe
European Patent Office1165183► Subscribe
Argentina029159► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Teva Womens Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2004Austria► SubscribePRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211
1214076/01Switzerland► SubscribePRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
0814Netherlands► SubscribePRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
2016 00016Denmark► SubscribePRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
C0002Belgium► SubscribePRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305
/2015Austria► SubscribePRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
156Luxembourg► SubscribePRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
2015000093Germany► SubscribePRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
McKinsey
Cerilliant
Chinese Patent Office
Moodys
US Army
Boehringer Ingelheim
Cipla
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot